THERAPIX BIOSCIENCES LTD. Inactive Instrument
Therapix Biosciences Ltd. Share Price Nasdaq
Equities
US88339A2033
Pharmaceuticals
| Sales 2022 | 1.35 112.35 | Sales 2023 | 2.88 240.14 | Capitalization | 2.56M 213M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -167M | Net income 2023 | -5M -417M | EV / Sales 2022 | 11,45,812 x |
| Net cash position 2022 | 3.55M 296M | Net cash position 2023 | 5M 417M | EV / Sales 2023 | -8,48,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +19.64% | 43.03B | |
| +23.86% | 22.7B | |
| +17.44% | 15.07B | |
| +23.64% | 14.77B | |
| +59.16% | 13.05B | |
| -0.05% | 6.79B | |
| -14.19% | 6.58B | |
| -8.87% | 5.73B | |
| +13.42% | 5.5B |
